path(HP:Stomatocytosis) association path(MESH:Thrombosis)

View Subject View Object

PubMed:25307023

Multiple haemolytic disorders and therapeutic interventions produce substantial intravascular haemolysis. Examples include PNH, SCD, thalassaemias, glucose-6-phosphate dehydrogenase (G6PD) deficiency, hereditary spherocytosis and stomatocytosis, pyruvate kinase deficiency, autoimmune haemolytic anaemia, microangiopathies, acute haemolytic transfusion reactions, mechanical circulatory support [e.g., left ventricular assist device (LVAD)/extracorporeal membrane oxygenation (ECMO)], RBC transfusions and infusions of RBC substitutes. These disorders, therapies and procedures are also associated with an increased risk of thrombosis.

Related Edges 34

• a(HM:"Glucose-6-phosphate dehydrogenase deficiency") increases path(MESH:Hemolysis)
• a(HM:"Glucose-6-phosphate dehydrogenase deficiency") association path(MESH:Thrombosis)
• a(HM:"acute hemolytic transfusion reaction") association path(MESH:Thrombosis)
• a(MESH:"Blood Substitutes") increases path(MESH:Hemolysis)
• a(MESH:"Blood Substitutes") association path(MESH:Thrombosis)
• a(MESH:"Blood Transfusion") increases path(MESH:Hemolysis)
• a(MESH:"Blood Transfusion") association path(MESH:Thrombosis)
• path(HP:"Paroxysmal nocturnal hemoglobinuria") increases path(MESH:Hemolysis)
• path(HP:"Paroxysmal nocturnal hemoglobinuria") association path(MESH:Thrombosis)
• path(HP:"autoimmune hemolytic anemia") increases path(MESH:Hemolysis)
• path(HP:"autoimmune hemolytic anemia") association path(MESH:Thrombosis)
• path(HP:Stomatocytosis) increases path(MESH:Hemolysis)
• path(MESH:"Anemia, Sickle Cell") increases path(MESH:Hemolysis)
• path(MESH:"Anemia, Sickle Cell") association path(MESH:Thrombosis)
• path(MESH:"Pyruvate Kinase Deficiency of Red Cells") increases path(MESH:Hemolysis)
• path(MESH:"Pyruvate Kinase Deficiency of Red Cells") association path(MESH:Thrombosis)
• path(MESH:"Spherocytosis, Hereditary") increases path(MESH:Hemolysis)
• path(MESH:"Spherocytosis, Hereditary") association path(MESH:Thrombosis)
• path(MESH:"Thrombotic Microangiopathies") increases path(MESH:Hemolysis)
• path(MESH:"Thrombotic Microangiopathies") association path(MESH:Thrombosis)
• path(MESH:Thalassemia) increases path(MESH:Hemolysis)
• path(MESH:Thalassemia) association path(MESH:Thrombosis)
• path(MESH:Thrombosis) association path(HP:"Paroxysmal nocturnal hemoglobinuria")
• path(MESH:Thrombosis) association path(MESH:"Anemia, Sickle Cell")
• path(MESH:Thrombosis) association path(MESH:Thalassemia)
• path(MESH:Thrombosis) association a(HM:"Glucose-6-phosphate dehydrogenase deficiency")
• path(MESH:Thrombosis) association path(MESH:"Spherocytosis, Hereditary")
• path(MESH:Thrombosis) association path(HP:Stomatocytosis)
• path(MESH:Thrombosis) association path(MESH:"Pyruvate Kinase Deficiency of Red Cells")
• path(MESH:Thrombosis) association path(HP:"autoimmune hemolytic anemia")
• path(MESH:Thrombosis) association path(MESH:"Thrombotic Microangiopathies")
• path(MESH:Thrombosis) association a(HM:"acute hemolytic transfusion reaction")
• path(MESH:Thrombosis) association a(MESH:"Blood Transfusion")
• path(MESH:Thrombosis) association a(MESH:"Blood Substitutes")

Cell Ontology (CL)

macrophage

MeSH

Plasma

MeSH

Urine

Text Location

Review

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.

---